URAPIDIL: MODERN MEDICINE FOR THE TREATMENT OF HYPERTENSIVE CRISES
https://doi.org/10.20996/1819-6446-2013-9-4-373-378
Abstract
Aim. To study the antihypertensive efficacy of urapidil, as well as to determine the optimal target level of systolic blood pressure (BP) in patients with hypertensive crisis complicated by a hemorrhagic stroke.
Material and methods. Patients (n=86) aged 46-87 years (42 men and 44 women) who were admitted to hospital with hypertensive crisis complicated by a hemorrhagic stroke were included into the study. Patients were randomized into two groups: standard treatment (n=20) or urapidil treatment (n=66). The efficacy of treatment was assessed by clinical data, BP and heart rate dynamics. Patient survival was also assessed.
Results. Mortality in urapidil group was 33% vs 70% in standard therapy group. Systolic BP in urapidil group decreased from 208 (203-222) mm Hg to 159 (149-180) and to
145 (141-153) mm Hg after 20 and 220 minutes, respectively, (p<0.001 for both), and diastolic BP from 108 (102-119) mm Hg to 90 (82-97) and 82 (80-90) mm Hg, re- spectively. Significant BP dynamics was also observed in standard therapy group. The target systolic BP level of 136-147 mm Hg was associated with better patient survival. Conclusion. The patients in urapidil group reached the target BP by the 20-th minute from the start of treatment, and this was accompanied by a better survival.
About the Authors
A. V. Melekhov
Russian National Research Medical University named after N.I. Pirogov, Moscow
Russian Federation
Russian Federation
Yu. I. Ostrovskaya
Russian National Research Medical University named after N.I. Pirogov, Moscow
Russian Federation
Russian Federation
References
1. TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013, 31:1281-1357
2. Diagnosis and treatment of hypertension. Russian recommendations (fourth revision). Systemic hypertension 2010 (3): 5-26. Russian (Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; (3): 5-26).
3. Van den Born BJ, Beutler JJ, Gaillard CA et al. Dutch guideline for the management of hypertensive crisis – 2010 revision. Neth J Med 2011;69(5):248-55.
4. Sarafidis PA, Georgianos PI, Malindretos P, Liakopoulos V. Pharmacological management of hypertensive emergencies and urgencies: focus on newer agents. Expert Opin Investig Drugs 2012;21(8):1089-106
5. Owens WB. Blood pressure control in acute cerebrovascular disease. J Clin Hypertens (Greenwich)2011;13(3):205-11.
6. Fredrich J. Butterworth J.I. Sodium nitroprusside: twenty years and counting. Anesth Analg 1995: 81:152-162.
7. Yao D, Jia S, Wang L et al. Therapeutic effect of urapidil on myocardial perfusion in patients with ST- elevation acute coronary syndrome. European Journal of Internal Medicine 2009; 20: 152-157.
8. Anger C, van Aken H, Feldhaus P et al. Permeation of the blood-brain barrier by urapidil and its influence on intracranial pressure in man in the presence of compromised intracranial dynamics. J Hyper- tens Suppl 1988;6(2):S63-4.
9. Bugnicourt JM, Duru C, Picard C, Godefroy O. Decrease in blood pressure after intravenous administration of urapidil during recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke. Clin Ther. 2008;30(9):1675-80.
Review
For citations:
Melekhov A.V., Ostrovskaya Yu.I. URAPIDIL: MODERN MEDICINE FOR THE TREATMENT OF HYPERTENSIVE CRISES. Rational Pharmacotherapy in Cardiology. 2013;9(4):373-378. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-4-373-378
Views:
1597
Email this article 